Prof. Dr. Eicke Latz
Institute of Innate Immunity
eicke.latz@uni-bonn.de View member: Prof. Dr. Eicke Latz
Molecular therapy. Nucleic acids
Long noncoding RNAs (lncRNAs) have emerged as biomarkers and regulators of cardiovascular disease. However, the expression pattern of circulating extracellular vesicle (EV)-incorporated lncRNAs in patients with coronary artery disease (CAD) is still poorly investigated. A human lncRNA array revealed that certain EV-lncRNAs are significantly dysregulated in CAD patients. Circulating small EVs (sEVs) from patients with (n = 30) or without (n = 30) CAD were used to quantify (also known as antisense RNA 1 []), , , and RNA levels. (p = 0.002) and (p = 0.02) were significantly increased in patients with CAD, compared to non-CAD patients. Fluorescent labeling and quantitative real-time PCR of sEVs demonstrated that functional was transported into the recipient cells. Mechanistically, the RNA-binding protein, heterogeneous nuclear ribonucleoprotein K (hnRNPK), interacts with , regulating its loading into sEVs. Knockdown of abrogated the EV-mediated effects on endothelial cell (EC) migration, proliferation, tube formation, and sprouting. Angiogenesis-related gene profiling showed that the expression of vascular endothelial growth factor A () RNA was significantly increased in EV recipient cells. Protein stability and RNA immunoprecipitation indicated that the -hnRNPK axis regulates the stability and binding of mRNA to hnRNPK. Loss of in EVs abolished the EV-mediated promotion of VEGFA gene and protein expression. Intercellular transfer of EV-incorporated promotes a pro-angiogenic phenotype via a VEGFA-dependent mechanism.
© 2021 The Authors.
PMID: 34484864
Institute of Innate Immunity
eicke.latz@uni-bonn.de View member: Prof. Dr. Eicke LatzMedical Clinic II for Cardiology, Angiology and Pneumology
georg.nickenig@ukbonn.de View member: Prof. Dr. med. Georg Nickenig